Genex Pharmaceutical Engages Leading Law Firm and Accounting Firm.TIANJIN, China -- Genex Pharmaceutical, Inc. (OTCBB OTCBB See OTC Bulletin Board (OTCBB). :GENX; website: www.genexpharm.com), a Delaware corporation, is a profitable biomedical technology company with a revolutionary product for treating various bone-related injuries called Reconstituted Bone Xenograft xenograft /xeno·graft/ (zen´o-graft) a graft of tissue transplanted between animals of different species; it may be concordant, (RBX), which is a medical device approved by the SFDA SFDA State Food and Drug Administration (China) SFDA Saudi Food & Drug Authority (Chinese State Food and Drug Administration The State Food and Drug Administration (SFDA Simplified Chinese: 国家食品药品监督管理局) is founded on the basis of the State Drug Administration. ). RBX is suitable for compound or complex bone fractures, compression fractures and intractable fractures, bone defects, vertebral column vertebral column: see spinal column. vertebral column or spinal column or spine or backbone Flexible column extending the length of the torso. or joint rehabilitation and for bone absence after tumor removal Tumor Removal Definition Tumor removal is a surgical procedure to remove an abnormal growth. Purpose A tumor can be either benign, like a wart, or malignant, in which case it is a cancer. such as a bone cyst cyst, abnormal sac in the body, filled with a fluid or semisolid and enclosed in a membrane. Cysts can be congenital but are usually acquired, the most common locations being the skin and the ovaries. . The Company announces that it has engaged the law firm of Holland & Knight (www.hklaw.com), a leading law firm with practice groups and industry-based teams comprised of more than 1200 lawyers and professionals worldwide to advise the Company as its SEC counsel. In addition, the Company has engaged Weinberg & Company, Inc. as its independent auditors. Mr. Fuzhi Song, Chairman and CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board. of Genex, stated, "As a public company, we are pleased to work with these highly qualified professionals to help us improve our business and potentially increase our visibility and credibility in the investment community. We appreciate the services that have been provided to us by our previous law firm and auditors. We look forward to releasing strong third quarter financial results ending September 30 in the near future." Genex Pharmaceutical's RBX is well suited to treat numerous bone-related injuries. Industry statistics estimate that over 15 million people in China suffer from some sort of bone defect, and the Company's RBX product is targeted to this potentially huge market. Other applications of RBX include treatment of dental decay, from which approximately 40 million people every year in China require treatment. About Genex Pharmaceutical, Inc. Genex Pharmaceutical, Inc. is a biomedical technology company with distinctive proprietary technology for an orthopedic device that treats bone-related injuries. Headquartered in Tianjin, China, the Company manufactures and distributes Reconstituted Bone Xenograft (RBX), to 400 hospitals in 22 provinces throughout mainland China. RBX is approved by the State Food and Drug Administration (SFDA) in China (the Chinese government agency that regulates drugs and medical devices). RBX offers a modern alternative to traditional methods of treating orthopedic injuries. Safe Harbor Safe Harbor 1. A legal provision to reduce or eliminate liability as long as good faith is demonstrated. 2. A form of shark repellent implemented by a target company acquiring a business that is so poorly regulated that the target itself is less attractive. Statement Statements about the Company's future expectations, including future revenue and earnings and all other statements in this press release, other than historical facts, are "forward-looking" statements and are made pursuant to safe harbor provisions of the Securities Exchange Act of 1934. Such forward-looking statements involve risks and uncertainties and are subject to change at any time. The Company's actual results could differ materially from expected results. In reflecting subsequent events or circumstances, the Company undertakes no obligation to update forward-looking statements. |
|
||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion